Telomir Pharmaceuticals, Inc. (TELO) company profile

Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company that develops small-molecule therapeutics targeting fundamental biological drivers of aging and age-related conditions. Its core scientific approach focuses on cellular mechanisms including metal-ion dysregulation, oxidative stress, epigenetic modification, mitochondrial dysfunction, and telomere integrity. The company's lead investigational compound, Telomir-1, is an orally administered molecule designed to modulate intracellular metal balance—specifically iron, copper, zinc, and calcium—through a regulated ion-exchange mechanism. Telomir evaluates this therapeutic candidate across multiple indications, including Wilson’s disease, Type 2 diabetes mellitus, and oncology models such as prostate, breast, and pancreatic cancers.

The company operates in the preclinical research phase, conducting in vitro and in vivo studies alongside computational modeling with third-party research collaborators. It is incorporated in Florida and maintains its principal executive offices in Miami, Florida. Telomir conducts its early-stage research in the United States and works with partner research organizations across global locations.

Summary of the business section of Telomir Pharmaceuticals's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“affecting approximately 1 in 30,000 individuals worldwide.”